Top Ten most popular articles on Pharmafile.com this week

pharmafile | January 26, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate 

As we come to the end of January, it’s Friday again – time for another rundown of the top ten most popular articles of Pharmafile.com this week.

GSK triumphed over rival firm Reckitt Benckiser in its legal battle, which saw the latter forced to withdraw its “misleading” advertising campaign trashing Glaxo’s panadeine product, while New York City’s mayoral administration launched a massive $500 million lawsuit against big pharma over their role in the opioid crisis.

The second-most popular story with our readers was one of the biggest stories of tthe week – Sanofi’s $11.6 billion deal for Bioverativ, which kicked offed M&As in 2018 after a stagnant 2017. But the most popular story this week was the news that major Indian pharma company has been reprimanded $5 million for improperly packaging its products.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. US court upholds ruling that J&J’s Remicade patent is invalid

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis drug Remicade (infliximab) is invalid.

9. 20,000 left disabled in UK due to sodium valproate use during pregnancy

20,000 children in the UK have been left with disabilities due to the use of anticonvulsant sodium valproate by mothers during pregnancy in the 1970s.

8. New York City launches $500 million lawsuit against big pharma over opioid crisis

The administration of New York City Mayor Bill de Blasio has announced its intention to bring legal action against the painkiller industry responsible for the ongoing opioid crisis in the US.

7. The measurement underpinning government goals for UK life sciences

Michael Adeogun, Head of Life Sciences and Health at National Physical Laboratory, discusses the importance of effective measurement for the life sciences industry in achieving the key goals outlined in Sir John Bell’s Life Sciences Industrial Strategy, the UK Government’s accompanying Sector Deal and beyond.

6. Amyloid pathway doubts after latest Alzheimer’s failure

There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible treatment, as well as raising serious doubts about the pursuit of removing amyloid plaques from the brain.

5. New vaccine provides universal protection against influenza A, study finds

Research led by Georgia State University has enabled the development of a universal vaccine for influenza A viruses, proven to provide long-lasting immunity in mice.

4. GSK wins case against Reckitt Benckiser over misleading ad campaign

GlaxoSmithKline is celebrating as it emerges that the UK pharma giant triumphed in its legal battle against Reckitt Benckiser after accusing the rival firm of misleading consumers.

3. Abcam acquires rights to over 700 Roche products in new licensing deal

Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 of the Swiss pharma giant’s products.

2. Sanofi finally seals big deal with $11.6bn for Bioverativ

Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify such desire into concrete results have often been commented upon. Now, it is able to put that narrative behind the company, with an $11.6 billion deal for Bioverativ.

1. Court fines Dr Reddy’s for improperly packaging products

A district court in the US handed down a $5 million penalty and entered a permanent injunction to prevent Dr. Reddy’s from distributing prescription drugs not in child-resistant packaging.

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …


Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease

Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem …

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental …

Latest content